These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 12596757)

  • 1. Assays for parathyroid hormone and their use in patients with end-stage renal disease.
    Goodman WG
    Blood Purif; 2003; 21(1):118-23. PubMed ID: 12596757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Parathyroid hormone (PTH), PTH-derived peptides, and new PTH assays in renal osteodystrophy.
    Goodman WG; Jüppner H; Salusky IB; Sherrard DJ
    Kidney Int; 2003 Jan; 63(1):1-11. PubMed ID: 12472763
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New assays for parathyroid hormone (PTH) and the relevance of PTH fragments in renal failure.
    Goodman WG
    Kidney Int Suppl; 2003 Nov; (87):S120-4. PubMed ID: 14531784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Similar predictive value of bone turnover using first- and second-generation immunometric PTH assays in pediatric patients treated with peritoneal dialysis.
    Salusky IB; Goodman WG; Kuizon BD; Lavigne JR; Zahranik RJ; Gales B; Wang HJ; Elashoff RM; Jüppner H
    Kidney Int; 2003 May; 63(5):1801-8. PubMed ID: 12675856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The evolution of assays for parathyroid hormone.
    Goodman WG
    Semin Dial; 2005; 18(4):296-301. PubMed ID: 16076352
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New PTH assays and renal osteodystrophy.
    Salusky IB; Jüppner H
    Pediatr Nephrol; 2004 Jul; 19(7):709-13. PubMed ID: 15173936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Specific measurement of PTH (1-84) in various forms of renal osteodystrophy (ROD) as assessed by bone histomorphometry.
    Lehmann G; Stein G; Hüller M; Schemer R; Ramakrishnan K; Goodman WG
    Kidney Int; 2005 Sep; 68(3):1206-14. PubMed ID: 16105052
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunoassays for the detection of parathyroid hormone.
    Jüppner H; Potts JT
    J Bone Miner Res; 2002 Nov; 17 Suppl 2():N81-6. PubMed ID: 12412782
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Practical considerations in PTH testing.
    Souberbielle JC; Friedlander G; Cormier C
    Clin Chim Acta; 2006 Apr; 366(1-2):81-9. PubMed ID: 16310759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The assay of the hypocalcemic PTH fragment inhibitor with PTH provides a more accurate assessment of renal osteodystrophy compared to the intact PTH assay.
    Cantor T; Sci B
    Nefrologia; 2003; 23 Suppl 2():69-72. PubMed ID: 12778858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Parathyroid hormone: new assays, new receptors.
    Martin KJ; Akhtar I; González EA
    Semin Nephrol; 2004 Jan; 24(1):3-9. PubMed ID: 14730504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The need for reliable serum parathyroid hormone measurements.
    Torres PU
    Kidney Int; 2006 Jul; 70(2):240-3. PubMed ID: 16838038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evolution of the parathyroid hormone (PTH) assay--importance of circulating PTH immunoheterogeneity and of its regulation.
    Gao P; D'Amour P
    Clin Lab; 2005; 51(1-2):21-9. PubMed ID: 15719701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Critical Governance Issue of Parathyroid Hormone Assays and its Selection in the Management of Chronic Kidney Disease Mineral and Bone Disorders.
    Kakuta T; Ishida M; Fukagawa M
    Ther Apher Dial; 2018 Jun; 22(3):220-228. PubMed ID: 29781225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lack of comparability of intact parathyroid hormone measurements among commercial assays for end-stage renal disease patients: implication for treatment decisions.
    Cantor T; Yang Z; Caraiani N; Ilamathi E
    Clin Chem; 2006 Sep; 52(9):1771-6. PubMed ID: 16858070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Parathyroid hormone variability parameters for identifying high turnover osteodystrophy disease in hemodialysis patients: an observational retrospective cohort study.
    De Paola L; Coppolino G; Bolignano D; Buemi M; Lombardi L
    Ther Apher Dial; 2010 Dec; 14(6):566-71. PubMed ID: 21118364
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of 1-84 and intact parathyroid hormone assay in pediatric dialysis patients.
    Sheth RD; Goldstein SL
    Pediatr Nephrol; 2005 Jul; 20(7):977-81. PubMed ID: 15856315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnosis of renal osteodystrophy: when and how to use biochemical markers and non-invasive methods; when bone biopsy is needed.
    Ferreira MA
    Nephrol Dial Transplant; 2000; 15 Suppl 5():8-14. PubMed ID: 11073268
    [No Abstract]   [Full Text] [Related]  

  • 19. Critical issues of PTH assays in CKD.
    Komaba H; Goto S; Fukagawa M
    Bone; 2009 Apr; 44(4):666-70. PubMed ID: 19159701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First- and second-generation immunometric PTH assays during treatment of hyperparathyroidism with cinacalcet HCl.
    Martin KJ; Jüppner H; Sherrard DJ; Goodman WG; Kaplan MR; Nassar G; Campbell P; Curzi M; Charytan C; McCary LC; Guo MD; Turner SA; Bushinsky DA
    Kidney Int; 2005 Sep; 68(3):1236-43. PubMed ID: 16105056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.